HUMA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HU

Mkt Cap

$118.1M

Volume

5.78M

Next Earnings

November 11th

Loading chart

HU

HUMAHumacyte, Inc. Common Stock

HUMA

Pay with—

Available Balance0.00

HU

Mkt Cap

$122.1M

Volume

5.78M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowHumacyte, Inc. (HUMA) declined 7.88% to close at $0.36, significantly underperforming the broader market. The stock has lost 30.55% over the past month, lagging the Medical sector's gains. Analysts expect the company to report a loss of $0.09 per share in the upcoming earnings release, though this represents a 35.71% year-over-year improvement. The company holds a Zacks Rank of #3 (Hold), with the Medical - Biomedical and Genetics industry ranked in the bottom 35% of all industries.Zacks Investment Research · Oct 13, 2026

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeHumacyte, Inc. (HUMA) closed at $0.48, down 4.26% on a day when major market indices gained. The stock has declined 17.34% over the past month, underperforming the Medical sector. The company is expected to report an EPS of -$0.09 and revenue of $0.86 million in its upcoming earnings release. Humacyte currently holds a Zacks Rank of #4 (Sell), and its industry ranks in the bottom 28% of all industries.Zacks Investment Research · Oct 6, 2026

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteHumacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors.Zacks Investment Research · Oct 1, 2026

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis AccessHumacyte, Inc. announced the appointment of two prominent nephrologists, Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury, as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. The appointments follow positive Phase 3 V012 study results in women and plans to file a supplemental Biologic License Application with the FDA.GlobeNewswire Inc. · Jul 14, 2026

Humacyte, Inc. Announces Pricing of Public Offering of Common StockHumacyte (NASDAQ: HUMA), a commercial-stage biotechnology company, announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, generating $50 million in gross proceeds. The company plans to use the funds to commercialize Symvess®, file a Biologics License Application supplement for hemodialysis indication, and develop pipeline candidates. The offering is expected to close on June 12, 2026.Benzinga · Jun 11, 2026

Humacyte, Inc. Announces Pricing of Public Offering of Common StockHumacyte, Inc. (Nasdaq: HUMA) announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, expected to raise $50 million in gross proceeds. The company plans to use the net proceeds to fund commercialization of Symvess®, advance pipeline development, and support general corporate purposes. The offering is expected to close on or about June 12, 2026.GlobeNewswire Inc. · Jun 11, 2026

Humacyte, Inc. Announces Proposed Public Offering of Common StockHumacyte, Inc. (Nasdaq: HUMA) announced an underwritten public offering of common stock with Barclays, BTIG, and Titan Partners as joint book-running managers. The company plans to use net proceeds to fund commercialization of Symvess®, file a supplemental BLA for hemodialysis indication, develop pipeline candidates, and support general corporate purposes.GlobeNewswire Inc. · Jun 11, 2026

Humacyte Announces First Quarter 2026 Financial Results and Provides Business UpdateHumacyte announced Q1 2026 financial results showing Symvess product revenue of $0.5M (up from $0.1M in Q1 2025) with 29 units sold. The company appointed industry veterans James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer to accelerate commercialization. Key upcoming milestone includes Phase 3 hemodialysis trial interim results on June 11, 2026. The company also received a $1.475M purchase commitment from Saudi Arabia and DoD funding for bioengineered blood vessels. Despite restructuring that reduced headcount by 25%, Humacyte expects $14.3M in cost savings for the remainder of 2026.GlobeNewswire Inc. · May 13, 2026

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical OfficerHumacyte announced that renowned vascular surgeon Dr. Todd E. Rasmussen has joined as Chief Surgical Officer. Dr. Rasmussen brings 28 years of military medical experience and current Mayo Clinic faculty status to support clinical adoption of Symvess and advance the company's bioengineered tissue pipeline toward regulatory approval.GlobeNewswire Inc. · May 12, 2026

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateHumacyte reported $2.0 million in total revenues for 2025 with 61 Symvess units sold. The company announced a $1.475 million purchase commitment from Saudi Arabia, FDA submission in Israel, and U.S. Department of Defense funding authorization. Key upcoming milestone includes top-line interim results from the V012 Phase 3 hemodialysis study expected in Q2 2026, with planned BLA filing in H2 2026. The company ended 2025 with $50.5 million in cash and secured a $77.5 million credit facility.GlobeNewswire Inc. · Mar 27, 2026

to start trading

HU

HUMAHumacyte, Inc. Common Stock

HUMA

Pay with—

Available Balance0.00

Your PositionYou don't own any HUMA yet.

Related Tickers

Earnings